Literature DB >> 3261276

Detection of human auto-anti-idiotypic antibodies (Ab2). II. Generation of Ab2 in atopic patients undergoing allergen immunotherapy.

J M Castracane1, R E Rocklin.   

Abstract

The present study demonstrates the cross-reactivity of a murine monoclonal antibody (MoAb) directed against purified ragweed antigen E (AgE) with human Ab1. This antiragweed AgE MoAb (clone SC7H.1G, IgM kappa) was used to detect Ab2 in the sera obtained from the three groups of subjects. Utilizing an ELISA assay, we found that immunoglobulins from 12 nonatopic subjects bound to a significantly greater extent to SC7H.1G (mean +/- SE; OD = 0.353 +/- 0.052) than immunoglobulins from 14 untreated ragweed atopics (OD = 0.149 +/- 0.020). However, immunoglobulins from 9 immunotherapy-treated patients (OD = 0.395 +/- 0.120) bound to the mouse anti-AgE MoAb to the same extent as nonatopic sera. Furthermore, an additional 7 patients with ragweed-allergic rhinitis were studied prospectively while undergoing immunotherapy and Ab2 levels were found to increase with time posttreatment. We also found an inverse correlation between Ab1 and Ab2 levels in the nonatopic and untreated atopic groups. These data indicate that immunotherapy stimulates the production of Ab2 in atopic patients and may be involved in the regulation of the antiragweed IgE response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261276     DOI: 10.1159/000234587

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  2 in total

1.  Detection of auto-anti-idiotypic antibodies to Lol p I (rye I) IgE antibodies in human sera by the use of murine idiotypes: levels in atopic and non-atopic subjects and effects of immunotherapy.

Authors:  J Hébert; D Bernier; W Mourad
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Anti-ids in allergy: timeliness of a classic concept.

Authors:  Julia Wallmann; Isabella Pali-Schöll; Erika Jensen-Jarolim
Journal:  World Allergy Organ J       Date:  2010-06       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.